Evidence map›Paper›PMID 37519644›Full record

ArticleHeliyon2023

Evaluation of vaccination coverage in heart failure patients in a tertiary center.

Adrien Maire, Nicolas Chapet, Sylvain Aguilhon, Marie-Lucie Laugier, Paul Laffont-Lozes, Mélinda Rigoni, Betty Mathieu, Yohan Audurier, Cyril Breuker, Gaëlle de Barry and 5 more

Open access · goldAbstract read
In one paragraph

Article in Heliyon, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 5 institutions in 1 country.

Adrien MaireClinical Pharmacy Department, University Hospital of Montpellier, Montpellier, France.
Nicolas ChapetClinical Pharmacy Department, University Hospital of Montpellier, Montpellier, France.
Sylvain AguilhonDepartment of Cardiology, University Hospital of Montpellier, Montpellier, France.
Marie-Lucie LaugierClinical Pharmacy Department, University Hospital of Montpellier, Montpellier, France.
Paul Laffont-LozesDepartment of Pharmacy, University Hospital of Nimes, Nimes, France.
Mélinda RigoniDepartment of Pharmacy, University Hospital of Nimes, Nimes, France.
Betty MathieuDepartment of Pharmacy, University Hospital of Nimes, Nimes, France.
Yohan AudurierPharmacy, Hospital of Amboise, Amboise, France.
Cyril BreukerClinical Pharmacy Department, University Hospital of Montpellier, Montpellier, France.
Gaëlle de BarryClinical Pharmacy Department, University Hospital of Montpellier, Montpellier, France.
Anne JalabertClinical Pharmacy Department, University Hospital of Montpellier, Montpellier, France.
Florence LeclercqDepartment of Cardiology, University Hospital of Montpellier, Montpellier, France.
Jean-Luc PasquiéDepartment of Cardiology, University Hospital of Montpellier, Montpellier, France.
François RoubilleDepartment of Cardiology, University Hospital of Montpellier, Montpellier, France.
Audrey Castet-NicolasClinical Pharmacy Department, University Hospital of Montpellier, Montpellier, France.
Centre Hospitalier Universitaire de Montpellier · FRCentre National de la Recherche Scientifique · FRUniversité de Nîmes · FRHôpital Ambroise-Paré · FRInserm · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Despite current recommendation, vaccination coverage (VC) for patients with heart failure (HF) remains far too limited. Aims: To evaluate the VC of HF patients followed in our hospital center and investigate the barriers to vaccination and the ways to address them. Methods: This was a cross-sectional monocentric descriptive study conducted between December 2019 and January 2021 at the University Hospital of Montpellier, France. Patients with HF history hospitalized in cardiology unit (CU) and patients in a HF telemonitoring program (TP) were included. An interview was conducted by a pharmacist to find out the patient's vaccination status against influenza and pneumococcus. For non-vaccinated patients, opinion and willingness to be vaccinated were also obtained. Results: Data from 335 patients were collected (185 in CU, 150 in TP). The mean age was 69.3 years and the proportion of males was 72%. About 65% were vaccinated against influenza in the last year (60% in CU, 72% in TP, p = 0.022) and 22% were up to date with pneumococcal vaccination (11% in CU, 35% in TP, p < 0.001). Among patients not vaccinated, 17% refused vaccination. Among unvaccinated patients who consider vaccination, 69% wanted to be vaccinated by their general practitioner (GP). Conclusions: The VC of HF patients remains insufficient. Patients in TP are more vaccinated than patients in CU, which could involve better management. The low rate of vaccinated patients is mainly explained by a lack of awareness. The medical team, including the clinical pharmacist by his dedicated time during medication reconciliation may play a major role in the management of hospitalized patients as well as GP's as local actors.

Indexed as

Clinical pharmacyHeart failureInfluenza vaccinationPneumococcal vaccinationVaccination coverage

Identifiers

PMID37519644
PMCPMC10372228
OpenAlexW4383653999

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.